Pediatric acute myeloid leukemia (AML) is a life-threatening blood cancer that interferes with the normal formation of blood cells, leaving children vulnerable to infection, bleeding, and relapse after treatment. Among the genetic changes linked to poor outcomes in pediatric AML, mutations in the gene ASXL1 are especially concerning, as children whose leukemia carries these mutations often have more aggressive disease and fewer effective treatment options. Under normal conditions, ASXL1 plays an important role in controlling gene activity by helping regulate how DNA is packaged inside cells. In leukemia, however, ASXL1 mutations almost always produce a shortened version of the protein that unexpectedly gains harmful new activity instead of losing function. This abnormal ASXL1 becomes part of a gene-regulating enzyme complex that becomes overly active, disrupting normal gene control. As a result, genes that drive leukemia growth and block healthy blood cell maturation are inappropriately turned on, contributing to disease development, progression, and relapse. While recent studies have revealed this abnormal enzyme activity as a key feature of ASXL1-mutant leukemia, we still do not understand how these mutations alter the molecular structure and behavior of the complex to cause disease. Filling this knowledge gap is essential for identifying new, more precise treatment strategies and ultimately improving outcomes for children affected by this aggressive form of AML.